BeiGene and Novartis’ unresectable hepatocellular carcinoma treatment is gaining ground as a potential treatment for advanced liver cancer. In the Phase III RATIONALE 301 trial of Tislelizumab as a first-line treatment, the drug met its primary endpoint of non-inferior overall survival compared to sorafenib alone.
The trial included over 600 patients with unresectable hepatocellular carcinoma, which is defined as a liver tumor not eligible for resection therapy given the extent of the disease. Scientists found the proposed drug to be generally safe. Its profile was consistent with previous observations, and zero new safety issues were raised. In addition to meeting the primary endpoint, Tislelizumab also met the secondary endpoints of overall response rate, durability of response, progression-free survival, time to progression per BIRC and other measures of tolerability, safety, and health-related quality of life.
Read more here